Identifying barriers and enablers for benzodiazepine (de)prescription: a qualitative study with patients and healthcare professionals.
Journal
Anales del sistema sanitario de Navarra
ISSN: 2340-3527
Titre abrégé: An Sist Sanit Navar
Pays: Spain
ID NLM: 9710381
Informations de publication
Date de publication:
17 Aug 2022
17 Aug 2022
Historique:
entrez:
17
8
2022
pubmed:
18
8
2022
medline:
19
8
2022
Statut:
epublish
Résumé
There has been a steadily growing trend in prescribing benzodiazepines over last decade. Spain is one of the countries where this class of drugs is most extensively prescribed by primary healthcare physicians. The aim of this study is to identify factors that might be acting as barriers and enablers for benzodiazepine (de)prescription from patient and professional perspectives. Qualitative study through semi-structured interviews with medical practitioners (n=17) and patients (n=27), and a nominal group with medical practitioners (n=19). Interviews were audio-recorded, transcribed and analyzed using thematic analysis. The analysis revealed key themes and was organized around barriers and enablers connected to three interrelated dimen-sions: the social and community context of prescription; the structure, organization and/or management of the health system, and the doctor-patient relationship. The excessive workload of professionals was widely cited as influencing over-prescription. (De)prescription of benzodiazepine was facilitated by encouraging the social prescription of health assets or developing strategies to therapeutic alliance processes and better doctor-patient communication. Our findings suggest that there is a role for the salutogenic approach and the health asset model in the development of a more person-centred clinical care. This study considers the importance of encouraging the use of non-pharmacological methods and techniques in the health system and promoting the creation of multidisciplinary teams, therapeutic alliance processes and better doctor-patient communication by giving professionals training in psychosocial skills.
Sections du résumé
BACKGROUND
BACKGROUND
There has been a steadily growing trend in prescribing benzodiazepines over last decade. Spain is one of the countries where this class of drugs is most extensively prescribed by primary healthcare physicians. The aim of this study is to identify factors that might be acting as barriers and enablers for benzodiazepine (de)prescription from patient and professional perspectives.
METHODS
METHODS
Qualitative study through semi-structured interviews with medical practitioners (n=17) and patients (n=27), and a nominal group with medical practitioners (n=19). Interviews were audio-recorded, transcribed and analyzed using thematic analysis.
RESULTS
RESULTS
The analysis revealed key themes and was organized around barriers and enablers connected to three interrelated dimen-sions: the social and community context of prescription; the structure, organization and/or management of the health system, and the doctor-patient relationship. The excessive workload of professionals was widely cited as influencing over-prescription. (De)prescription of benzodiazepine was facilitated by encouraging the social prescription of health assets or developing strategies to therapeutic alliance processes and better doctor-patient communication.
CONCLUSION
CONCLUSIONS
Our findings suggest that there is a role for the salutogenic approach and the health asset model in the development of a more person-centred clinical care. This study considers the importance of encouraging the use of non-pharmacological methods and techniques in the health system and promoting the creation of multidisciplinary teams, therapeutic alliance processes and better doctor-patient communication by giving professionals training in psychosocial skills.
Identifiants
pubmed: 35975325
pii: e1005
doi: 10.23938/ASSN.1005
pmc: PMC10130797
doi:
pii:
Substances chimiques
Benzodiazepines
12794-10-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Health Promot Int. 2021 Aug 24;36(3):884-894
pubmed: 32968813
Am J Manag Care. 2016 May;22(5):370-6
pubmed: 27266438
BMJ. 2005 Nov 19;331(7526):1169
pubmed: 16284208
Clin Med (Lond). 2010 Apr;10(2):130-3
pubmed: 20437981
Pharmacy (Basel). 2019 Jul 25;7(3):
pubmed: 31349584
Eur J Clin Pharmacol. 2015 Dec;71(12):1415-27
pubmed: 26407687
Patient. 2017 Feb;10(1):1-15
pubmed: 27282559
BMJ. 2014 Sep 09;349:g5205
pubmed: 25208536
Calcif Tissue Int. 2012 Jul;91(1):24-31
pubmed: 22566242
Qual Health Res. 2016 Mar;26(4):466-81
pubmed: 25800715
Sleep Med. 2008 Dec;9(8):818-22
pubmed: 18226959
Br J Psychiatry. 2014 Jun;204(6):471-9
pubmed: 24526745
Qual Quant. 2018;52(4):1893-1907
pubmed: 29937585
J Gen Intern Med. 2018 Jun;33(6):892-897
pubmed: 29299815
Health Soc Care Community. 2017 Jan;25(1):194-203
pubmed: 26455723
BMC Fam Pract. 2020 Jun 8;21(1):100
pubmed: 32513110
J Child Psychol Psychiatry. 2018 Jan;59(1):5-19
pubmed: 28681928
PLoS One. 2012;7(11):e49113
pubmed: 23145088
Qual Health Res. 2017 Nov;27(13):2030-2041
pubmed: 28891380
Thorax. 2013 Feb;68(2):163-70
pubmed: 23220867
BMJ Open. 2019 Feb 3;9(2):e023810
pubmed: 30782888
Semergen. 2016 Jan-Feb;42(1):2-10
pubmed: 25554433
Cochrane Database Syst Rev. 2015;(5):CD009652
pubmed: 26106751
Scand J Prim Health Care. 2007 Dec;25(4):214-9
pubmed: 18041658
BMC Fam Pract. 2013 Dec 13;14:191
pubmed: 24330388
J Med Internet Res. 2017 Jun 16;19(6):e214
pubmed: 28623184
J Med Internet Res. 2017 Sep 28;19(9):e286
pubmed: 28958986
Int J Environ Res Public Health. 2021 Jun 01;18(11):
pubmed: 34205985
BMC Psychiatry. 2016 Aug 04;16:274
pubmed: 27488186
BMC Fam Pract. 2014 May 15;15:99
pubmed: 24885812
Int J Clin Pract. 2021 Jun;75(6):e14084
pubmed: 33555081